Tag: Cancer Drug Development
Pathos AI Expands Oncology Pipeline Through Strategic Deals with Alphamab and AstraZeneca
Pathos AI announced two separate licensing and co-development agreements with Alphamab Oncology and AstraZeneca, expanding its clinical-stage pipeline of targeted cancer therapies using its proprietary platform,...
AstraZeneca Licenses Novel Lung Cancer Drug Zegfrovy in $1.5B Global Deal
AstraZeneca announced a exclusive global license agreement with Dizal Pharmaceutical to develop and commercialize Zegfrovy (sunvozertinib), a highly differentiated, oral irreversible EGFR inhibitor designed for targeted lung cancer...
GSK Launches Tender Offer to Acquire Precision Oncology Innovator Nuvalent, Inc.at $124.00
GSK plc has officially commenced a tender offer to acquire all issued and outstanding shares of Class A and Class B common stock of Nuvalent,...
